001454546 000__ 05635cam\a2200493\i\4500
001454546 001__ 1454546
001454546 003__ OCoLC
001454546 005__ 20230314003217.0
001454546 006__ m\\\\\o\\d\\\\\\\\
001454546 007__ cr\cn\nnnunnun
001454546 008__ 230210s2023\\\\sz\a\\\\ob\\\\001\0\eng\d
001454546 019__ $$a1368316666$$a1368340895$$a1368351150$$a1368380915
001454546 020__ $$a9783031143397$$q(electronic bk.)
001454546 020__ $$a3031143396$$q(electronic bk.)
001454546 020__ $$z9783031143380
001454546 020__ $$z3031143388
001454546 0247_ $$a10.1007/978-3-031-14339-7$$2doi
001454546 035__ $$aSP(OCoLC)1369581678
001454546 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dEBLCP$$dYDX
001454546 049__ $$aISEA
001454546 050_4 $$aRC386.2
001454546 08204 $$a174.2/9689$$223/eng/20230210
001454546 24500 $$aEthics and clinical neuroinnovation :$$bfundamentals, stakeholders, case studies, and emerging issues /$$cLaura Weiss Roberts, editor.
001454546 264_1 $$aCham :$$bSpringer,$$c[2023]
001454546 264_4 $$c©2023
001454546 300__ $$a1 online resource (xii, 353 pages) :$$billustrations (some color)
001454546 336__ $$atext$$btxt$$2rdacontent
001454546 337__ $$acomputer$$bc$$2rdamedia
001454546 338__ $$aonline resource$$bcr$$2rdacarrier
001454546 504__ $$aIncludes bibliographical references and index.
001454546 5050_ $$aSection 1: Fundamentals: the imperative for novel clinical therapeutics for mental disorders -- Chapter 1: The case for neuroinnovation: Health burdens associated with psychiatric, addiction-related, and co-occurring disorders -- Chapter 02: Neuroinnovation in medicine: History and future -- Chapter 03: Clinical neuroinnovation: Ethical frameworks and emerging issues -- Chapter 04: Changing contexts of neuroinnovation: Societal considerations -- Chapter 05: Changing contexts of neuroinnovation: Societal considerations -- Chapter 06: The NIHs BRAIN2025 agenda: Attention to related ethical considerations -- Section 2: Special Topics in Clinical Neuroinnovation -- Chapter 07: In the surgical suite: Neurosurgery and neuroinnovation, and the ethics of neurostimulation for severe obesity -- Chapter 08: In the midst of uncertainty: Neuroinnovation at the edge of consciousness -- Chapter 09: On the edges: The ethics of human studies with psychedelic substances -- Chapter 10: In the courts: Emerging neuroscience technologies used for forensic purposes: ethical and legal implications -- Chapter 11: Into the wild: A comment on neuroethics startups - Moving from lab to society -- Section 3: Neuroethics and Innovation: Inquiry informed by the Roberts Valence Model -- Chapter 12: Introduction to our project: Understanding ethically-salient perspectives of diverse societal stakeholders in innovative neuroscience research on mental disorders -- Chapter 13: Qualitative phase: Codebook development -- Chapter 14: Qualitative findings: Diverse stakeholder perspectives on ethical considerations in innovative neuroscience research involving human volunteers -- Chapter 15: Qualitative findings: A focus on professional stakeholder perspectives on the environments and challenges of innovative neuroscience research -- Chapter 16: Qualitative findings: A focus on professional stakeholder perspectives on additional issues in research and clinical innovation in the brain -- Chapter 17: Pilot quantitative phase: Amazon MTurk as a novel approach to stakeholder-based neuroethics survey research.
001454546 506__ $$aAccess limited to authorized users.
001454546 520__ $$aNew ways of understanding the brain its nature, its capacities, its function, and its dysfunction hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances. An introduction to the imperative to develop new treatments for devastating brain disorders and the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists and neuroethicists outline the clinical and the ethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly written contributions on novel qualitative and quantitative data from stakeholders in the field, including neuroscientist-clinicians, people living with mental illness and/or addictions, and oversight/policy stakeholders. Concise, anticipatory, and centered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law.
001454546 588__ $$aDescription based on print version record.
001454546 650_0 $$aBrain$$xDiseases$$xTreatment$$xMoral and ethical aspects.
001454546 655_0 $$aElectronic books.
001454546 7001_ $$aRoberts, Laura Weiss,$$d1960-$$eeditor.
001454546 77608 $$iPrint version:$$tEthics and clinical neuroinnovation.$$dCham : Springer, 2022$$z9783031143380$$w(OCoLC)1346929184
001454546 852__ $$bebk
001454546 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-14339-7$$zOnline Access$$91397441.1
001454546 909CO $$ooai:library.usi.edu:1454546$$pGLOBAL_SET
001454546 980__ $$aBIB
001454546 980__ $$aEBOOK
001454546 982__ $$aEbook
001454546 983__ $$aOnline
001454546 994__ $$a92$$bISE